<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1817">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137509</url>
  </required_header>
  <id_info>
    <org_study_id>AHGNH</org_study_id>
    <nct_id>NCT05137509</nct_id>
  </id_info>
  <brief_title>YKL -40 as New Biomarker in COVID -19 Patients</brief_title>
  <official_title>YKL -40 as Anew Biomarker in COVID -19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronavirus disease-2019 (COVID-19)is a pandemic disease caused by SARS -COV-2 which&#xD;
      belongs to the β-coronavirus family . The majority of affected individuals exhibit no or mild&#xD;
      to moderate symptoms, but up to 15% of patients develop severe pneumonia with approximately&#xD;
      6% progressing to acute respiratory distress syndrome and multiorgan failure.&#xD;
&#xD;
      Biomarkers are needed to identify patients will suffer rapid disease progression to severe&#xD;
      complications and death. Preliminary studies describe vasculitic processes underlying organ&#xD;
      damage in seriously ill patients, induced by the activation of inflammatory cascades,&#xD;
      complement activation and pro-inflammatory cytokines (i.e. interleukin).&#xD;
&#xD;
      The severity of Vasculitic damage is unfortunately not easily predictable through currently&#xD;
      used laboratory biomarkers such as D-dimer or prothrombin time/activated partial&#xD;
      thromboplastin time.&#xD;
&#xD;
      The severity of the disease is mainly driven by diffuse interstitial lung diseases. YKL-40&#xD;
      has a pro mitogenic action on pulmonary fibroblasts, increases the activity of macrophages&#xD;
      and is associated with inflammatory disorders. In ILD, YKL-40 has been described to be&#xD;
      associated with the severity of lung diseases and with the risk of death.&#xD;
&#xD;
      YKL-40 serum levels could therefore be of interest for diagnosis and prognosis since it is at&#xD;
      the cross-link between vascular and epithelial lung damage.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2022</start_date>
  <completion_date type="Anticipated">December 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Using YKL -40 to help in diagnosis of COVID -19 and assessment of disease severity</measure>
    <time_frame>2 years</time_frame>
    <description>1- To highlight the role of YKL-40 biomarker in diagnosis of COVID -19 and assessment of disease severity.&#xD;
2- To compare the sensitivity and the specificity of YKL- 40 in relation to other biomarkers used in diagnosis of Covid-19.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)</arm_group_label>
    <description>Patients Infected by COVID -19 diagnosed by Reverse transcriptase polymerase chain reaction and computerized tomography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients suffering from chronic lung disease</arm_group_label>
    <description>Diagnosed by clinical manifestation and Computerized tomogarphy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Individuals</arm_group_label>
    <description>They must be without prior history of chronic inflammation in the lung</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Computerized Tomography</intervention_name>
    <description>Using Computerized Tomography for diagnosis COVID -19 patients</description>
    <arm_group_label>Patients Infected by severe acute respiratory syndrome coronavirus 2 (SARS-cov-2)</arm_group_label>
    <arm_group_label>patients suffering from chronic lung disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients come to Assiut university with clinical manifestation of COVID -19&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Group one should be diagnosed by RT-PCR (reverse transcriptase polymerase chain&#xD;
             reaction).&#xD;
&#xD;
               -  Healthy individual must be without a prior history of chronic inflammation in the&#xD;
                  lung.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with acute renal failure (ARF) or multiple organ damage (MOF).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sohair K Sayed, professor</last_name>
    <phone>0102447771</phone>
    <email>Ksoher3@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abeer A mokhtar, lecturer</last_name>
    <phone>01008792989</phone>
    <email>Abeermokhtar2010@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013 Oct;21(10):544-55. doi: 10.1016/j.tim.2013.05.005. Epub 2013 Jun 14. Review.</citation>
    <PMID>23770275</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020 Jan 28;9(1):221-236. doi: 10.1080/22221751.2020.1719902. eCollection 2020. Erratum in: Emerg Microbes Infect. 2020 Dec;9(1):540.</citation>
    <PMID>31987001</PMID>
  </results_reference>
  <results_reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </results_reference>
  <results_reference>
    <citation>Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest. 2020 Aug;158(2):646-659. doi: 10.1016/j.chest.2020.03.037. Epub 2020 Apr 5. Review.</citation>
    <PMID>32268131</PMID>
  </results_reference>
  <results_reference>
    <citation>Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med. 2011 Jan;105(1):106-13. doi: 10.1016/j.rmed.2010.09.012.</citation>
    <PMID>20888745</PMID>
  </results_reference>
  <results_reference>
    <citation>Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein. Antiviral Res. 2018 Jan;149:58-74. doi: 10.1016/j.antiviral.2017.11.001. Epub 2017 Nov 8. Review.</citation>
    <PMID>29128390</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang XZ. [CT investigation of spinal injury]. Zhonghua Fang She Xue Za Zhi. 1988 Aug;22(4):227-30. Chinese.</citation>
    <PMID>3208584</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Norhan mostafa Mohamed Abdelal</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

